Cytokinetics Quarterly Income Statement
NASDAQ: CYTKHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Cytokinetics revenue and earnings
In the quarter ended Jun 30, 2026, Cytokinetics generated $28.6 million in revenue, down 57.1% from the same quarter a year earlier. Cytokinetics reported a net loss of $198.8 million, compared with a loss of $134.4 million a year earlier. Operating margin was -626.0%.
Diluted earnings per share came in at -$1.50.
Summary generated from market data by MetaCap's automated system. Methodology
Cytokinetics income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 28.62M | 19.36M | 17.75M | 1.94M | 66.77M | 1.58M | 16.93M | 463.00K | 249.00K | 835.00K | 1.67M | 378.00K |
| Revenue growth (YoY) | -57.13% | +1125.78% | +4.89% | +318.14% | +26714.86% | +89.10% | +912.38% | +22.49% | -71.28% | -81.90% | -14.56% | -84.97% |
| Operating Expenses | 207.80M | 202.97M | 196.12M | 168.69M | 178.28M | 157.21M | 155.97M | 141.26M | 130.42M | 127.07M | 129.09M | 122.64M |
| Research & Development | 97.81M | 95.53M | 104.40M | 99.23M | 110.14M | 98.26M | 93.63M | 84.61M | 79.60M | 81.57M | 84.98M | 82.53M |
| Selling, General & Admin | 104.40M | 104.90M | — | — | 65.72M | 57.37M | — | — | — | — | — | — |
| Operating Income | -179.17M | -183.62M | -178.37M | -166.75M | -111.51M | -155.63M | -139.04M | -140.80M | -130.17M | -126.23M | -127.42M | -122.27M |
| Interest Expense | — | — | 14.27M | 11.35M | 11.08M | — | 8.94M | 8.93M | 12.73M | 7.10M | 7.16M | 7.14M |
| Other Income (Expense) | 13.94M | 11.02M | 11.47M | 10.25M | 13.00M | 13.70M | 15.01M | 17.05M | 11.55M | 7.91M | 7.59M | 6.84M |
| Net Income | -198.76M | -206.03M | -183.03M | -306.18M | -134.37M | -161.38M | -150.02M | -160.54M | -143.32M | -135.64M | -136.90M | -129.42M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -1.50 | -1.67 | -1.51 | -2.55 | -1.12 | -1.36 | -1.26 | -1.36 | -1.31 | -1.33 | -1.38 | -1.35 |
| EPS (Diluted) | -1.50 | -1.67 | -1.51 | -2.55 | -1.12 | -1.36 | -1.26 | -1.36 | -1.31 | -1.33 | -1.38 | -1.35 |
| Shares Outstanding (Basic) | 132.09K | 123.27K | — | 119.98K | 119.46K | 118.50K | — | 117.69K | 109.24K | 101.92K | — | 96.07K |
| Shares Outstanding (Diluted) | 132.09K | 123.27K | — | 119.98K | 119.46K | 118.50K | — | 117.69K | 109.24K | 101.92K | — | 96.07K |
| EBITDA | -175.54M | -180.24M | -175.50M | -164.08M | -109.22M | -153.33M | -136.66M | -138.39M | -127.77M | -123.90M | -121.08M | -120.41M |
| Operating Margin | -625.95% | -948.69% | -1004.60% | -8613.38% | -167.00% | -9856.30% | -821.41% | -30410.58% | -52277.91% | -15117.96% | -7620.69% | -32345.24% |
| Net Margin | -694.39% | -1064.48% | -1030.87% | -15814.98% | -201.25% | -10220.14% | -886.28% | -34674.95% | -57557.43% | -16244.67% | -8187.56% | -34238.62% |
This table shows 12 quarterly periods of Cytokinetics's income statement, from Q2 2026 back to Q3 2023, across 17 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow CYTK's reporting calendar. What is a income statement?